COVID-19 and risks to the supply and quality of tests, drugs, and vaccines
Paul N. Newton(Boston University), Eurek Ranjit, Pierre Claver Kayumba, Souly Phanouvong, Michael Deats, Murray Lumpkin, Mirza Lalani, Wilbert Bannenberg, Ayenew Ashenef, Ghulam Rahim Awab, Stephen Kigera, Philip E. Coyne, Bernard Naughton, Catherine Dujardin, Nicholas Day(John Radcliffe Hospital), Marya Lieberman, Sachiko Ozawa(University of North Carolina at Chapel Hill), Facundo M. Fernández, Cassandra Kelly, Elizabeth Pisani, Tim K. Mackey(University of California San Diego), Lutz Heide, Peter Horby, Marie Antignac, Chioma Ejekam, Aleisha Brock, Marie Lamy, Jason Bower, Oksana Pyzik, Marie Gill, Lembit Rägo, Moji Christianah Adeyeye, Kazuko Kimura, Céline Caillet, Anushka Patel(The University of Sydney), Georgina Joan Harigwo, Kim Doyle, Harparkash Kaur(London School of Hygiene & Tropical Medicine), Mohammad Sofiqur Rahman, Clark C. Freifeld, Kawtar Douidy, Piero Olliaro, Katherine C. Bond(Novel Health Strategies (United States)), Philip Nguyen, Zaheer-Ud-Din Babar, Philippe J. Guérin, Joel G. Breman, Felix Khuluza
Cited by 167
Related Papers
Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes
|New England Journal of Medicine|2008|7.4k
Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial
|The Lancet|2020|3.7k
Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19
|JAMA|2020|2.4k
A minimal common outcome measure set for COVID-19 clinical research
|The Lancet Infectious Diseases|2020|1.8k
Avian Influenza A (H5N1) in 10 Patients in Vietnam
|New England Journal of Medicine|2004|840